vs
Side-by-side financial comparison of Dianthus Therapeutics, Inc. (DNTH) and Sintx Technologies, Inc. (SINT). Click either name above to swap in a different company.
Sintx Technologies, Inc. is the larger business by last-quarter revenue ($290.0K vs $284.0K, roughly 1.0× Dianthus Therapeutics, Inc.). Sintx Technologies, Inc. runs the higher net margin — -763.8% vs -22687.3%, a 21923.5% gap on every dollar of revenue. On growth, Sintx Technologies, Inc. posted the faster year-over-year revenue change (-46.5% vs -78.6%). Sintx Technologies, Inc. produced more free cash flow last quarter ($-2.4M vs $-47.1M). Over the past eight quarters, Sintx Technologies, Inc.'s revenue compounded faster (-35.0% CAGR vs -44.6%).
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
Sintx Technologies, Inc. is an advanced materials company specializing in R&D and manufacturing of high-performance silicon nitride and other technical ceramic products. It serves key segments including medical implants, aerospace & defense, industrial wear components, and electric vehicle applications, with core markets across North America, Europe and Asia-Pacific.
DNTH vs SINT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0K | $290.0K |
| Net Profit | $-64.4M | $-2.2M |
| Gross Margin | — | 64.8% |
| Operating Margin | -24486.3% | -799.3% |
| Net Margin | -22687.3% | -763.8% |
| Revenue YoY | -78.6% | -46.5% |
| Net Profit YoY | -126.6% | -30.7% |
| EPS (diluted) | $-1.53 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0K | $290.0K | ||
| Q3 25 | $396.0K | $208.0K | ||
| Q2 25 | — | $151.0K | ||
| Q1 25 | $1.2M | $369.0K | ||
| Q4 24 | $1.3M | $542.0K | ||
| Q3 24 | $2.2M | $799.0K | ||
| Q2 24 | $1.9M | $859.0K | ||
| Q1 24 | $874.0K | $687.0K |
| Q4 25 | $-64.4M | $-2.2M | ||
| Q3 25 | $-36.8M | $-3.5M | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | $-29.5M | $-2.3M | ||
| Q4 24 | $-28.4M | $-1.7M | ||
| Q3 24 | $-25.2M | $-6.2M | ||
| Q2 24 | $-17.6M | $-2.2M | ||
| Q1 24 | $-13.7M | $-886.0K |
| Q4 25 | — | 64.8% | ||
| Q3 25 | — | 44.7% | ||
| Q2 25 | — | 37.7% | ||
| Q1 25 | — | 33.3% | ||
| Q4 24 | — | 71.6% | ||
| Q3 24 | — | 73.7% | ||
| Q2 24 | — | 73.9% | ||
| Q1 24 | — | 67.5% |
| Q4 25 | -24486.3% | -799.3% | ||
| Q3 25 | -10173.7% | -1613.0% | ||
| Q2 25 | — | -1764.9% | ||
| Q1 25 | -2852.7% | -645.8% | ||
| Q4 24 | -2406.9% | -319.6% | ||
| Q3 24 | -1376.6% | -802.0% | ||
| Q2 24 | -1191.8% | -315.5% | ||
| Q1 24 | -2041.6% | -465.4% |
| Q4 25 | -22687.3% | -763.8% | ||
| Q3 25 | -9284.1% | -1701.4% | ||
| Q2 25 | — | -1535.1% | ||
| Q1 25 | -2537.5% | -621.1% | ||
| Q4 24 | -2144.8% | -312.7% | ||
| Q3 24 | -1159.0% | -780.9% | ||
| Q2 24 | -945.1% | -256.6% | ||
| Q1 24 | -1573.0% | -129.0% |
| Q4 25 | $-1.53 | $-0.50 | ||
| Q3 25 | $-0.97 | $-3.46 | ||
| Q2 25 | — | $-0.91 | ||
| Q1 25 | $-0.82 | $-1.29 | ||
| Q4 24 | $-0.76 | $17.04 | ||
| Q3 24 | $-0.74 | $-6.96 | ||
| Q2 24 | $-0.51 | $-3.61 | ||
| Q1 24 | $-0.54 | $-21.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $404.3M | $4.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $493.4M | $2.9M |
| Total Assets | $530.9M | $9.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $404.3M | $4.1M | ||
| Q3 25 | $402.6M | $6.3M | ||
| Q2 25 | — | $4.3M | ||
| Q1 25 | $263.2M | $6.5M | ||
| Q4 24 | $275.2M | $3.6M | ||
| Q3 24 | $281.1M | $4.8M | ||
| Q2 24 | $360.7M | $4.6M | ||
| Q1 24 | $377.0M | $5.8M |
| Q4 25 | $493.4M | $2.9M | ||
| Q3 25 | $546.5M | $4.1M | ||
| Q2 25 | — | $4.0M | ||
| Q1 25 | $328.6M | $6.1M | ||
| Q4 24 | $352.5M | $3.9M | ||
| Q3 24 | $337.9M | $5.6M | ||
| Q2 24 | $358.2M | $8.8M | ||
| Q1 24 | $372.7M | $9.9M |
| Q4 25 | $530.9M | $9.5M | ||
| Q3 25 | $577.4M | $11.4M | ||
| Q2 25 | — | $9.2M | ||
| Q1 25 | $348.6M | $11.4M | ||
| Q4 24 | $374.0M | $9.4M | ||
| Q3 24 | $354.2M | $11.3M | ||
| Q2 24 | $369.0M | $15.3M | ||
| Q1 24 | $382.5M | $17.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-47.0M | $-2.3M |
| Free Cash FlowOCF − Capex | $-47.1M | $-2.4M |
| FCF MarginFCF / Revenue | -16591.9% | -822.8% |
| Capex IntensityCapex / Revenue | 48.6% | 14.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-132.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-47.0M | $-2.3M | ||
| Q3 25 | $-30.6M | $-2.5M | ||
| Q2 25 | — | $-2.4M | ||
| Q1 25 | $-27.6M | $-1.3M | ||
| Q4 24 | $-27.4M | $-1.1M | ||
| Q3 24 | $-21.3M | $-2.6M | ||
| Q2 24 | $-14.5M | $-2.2M | ||
| Q1 24 | $-14.9M | $-2.7M |
| Q4 25 | $-47.1M | $-2.4M | ||
| Q3 25 | $-30.6M | $-2.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | $-27.7M | $-1.4M | ||
| Q4 24 | $-27.5M | $-1.3M | ||
| Q3 24 | $-21.3M | $-2.6M | ||
| Q2 24 | $-14.5M | $-2.6M | ||
| Q1 24 | $-15.0M | $-2.9M |
| Q4 25 | -16591.9% | -822.8% | ||
| Q3 25 | -7717.2% | -1250.5% | ||
| Q2 25 | — | — | ||
| Q1 25 | -2377.8% | -368.6% | ||
| Q4 24 | -2072.0% | -234.3% | ||
| Q3 24 | -980.3% | -323.0% | ||
| Q2 24 | -780.7% | -299.7% | ||
| Q1 24 | -1713.2% | -423.1% |
| Q4 25 | 48.6% | 14.5% | ||
| Q3 25 | 1.3% | 40.4% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | 2.1% | 16.0% | ||
| Q4 24 | 2.3% | 26.9% | ||
| Q3 24 | 1.2% | 1.4% | ||
| Q2 24 | 0.9% | 41.8% | ||
| Q1 24 | 3.7% | 25.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
